These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 21376127)

  • 1. Functional biomarkers of musculoskeletal syndrome (MSS) for early in vivo screening of selective MMP-13 inhibitors.
    Mazurek SG; Li J; Nabozny GH; Reinhart GA; Muthukumarana AC; Harrison PC; Fryer RM
    J Pharmacol Toxicol Methods; 2011; 64(1):89-96. PubMed ID: 21376127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats.
    Renkiewicz R; Qiu L; Lesch C; Sun X; Devalaraja R; Cody T; Kaldjian E; Welgus H; Baragi V
    Arthritis Rheum; 2003 Jun; 48(6):1742-9. PubMed ID: 12794843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
    Baragi VM; Becher G; Bendele AM; Biesinger R; Bluhm H; Boer J; Deng H; Dodd R; Essers M; Feuerstein T; Gallagher BM; Gege C; Hochgürtel M; Hofmann M; Jaworski A; Jin L; Kiely A; Korniski B; Kroth H; Nix D; Nolte B; Piecha D; Powers TS; Richter F; Schneider M; Steeneck C; Sucholeiki I; Taveras A; Timmermann A; Van Veldhuizen J; Weik J; Wu X; Xia B
    Arthritis Rheum; 2009 Jul; 60(7):2008-18. PubMed ID: 19565489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects.
    King J; Zhao J; Clingan P; Morris D
    Anticancer Res; 2003; 23(1B):639-45. PubMed ID: 12680160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat.
    Nénan S; Lagente V; Planquois JM; Hitier S; Berna P; Bertrand CP; Boichot E
    Eur J Pharmacol; 2007 Mar; 559(1):75-81. PubMed ID: 17234180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors.
    Peterson JT
    Cardiovasc Res; 2006 Feb; 69(3):677-87. PubMed ID: 16413004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease.
    Treharne GD; Boyle JR; Goodall S; Loftus IM; Bell PR; Thompson MM
    Br J Surg; 1999 Aug; 86(8):1053-8. PubMed ID: 10460642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interaction of metal ions and Marimastat with matrix metalloproteinase 9.
    Underwood CK; Min D; Lyons JG; Hambley TW
    J Inorg Biochem; 2003 Jun; 95(2-3):165-70. PubMed ID: 12763661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen.
    Primrose JN; Bleiberg H; Daniel F; Van Belle S; Mansi JL; Seymour M; Johnson PW; Neoptolemos JP; Baillet M; Barker K; Berrington A; Brown PD; Millar AW; Lynch KP
    Br J Cancer; 1999 Feb; 79(3-4):509-14. PubMed ID: 10027321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours.
    Wall L; Talbot DC; Bradbury P; Jodrell DI
    Br J Cancer; 2004 Feb; 90(4):800-4. PubMed ID: 14970856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marimastat: the clinical development of a matrix metalloproteinase inhibitor.
    Steward WP; Thomas AL
    Expert Opin Investig Drugs; 2000 Dec; 9(12):2913-22. PubMed ID: 11093361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA.
    Watson SA; Morris TM; Collins HM; Bawden LJ; Hawkins K; Bone EA
    Br J Cancer; 1999 Sep; 81(1):19-23. PubMed ID: 10487607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marimastat inhibits neointimal thickening in a model of human vein graft stenosis.
    Porter KE; Loftus IM; Peterson M; Bell PR; London NJ; Thompson MM
    Br J Surg; 1998 Oct; 85(10):1373-7. PubMed ID: 9782017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The matrix metalloproteinase inhibitor marimastat inhibits seizures in a model of kainic acid-induced status epilepticus.
    Pijet B; Konopka A; Rejmak E; Stefaniuk M; Khomiak D; Bulska E; Pikul S; Kaczmarek L
    Sci Rep; 2020 Dec; 10(1):21314. PubMed ID: 33277582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dynamic changes of MMP-1, MMP-9 and TIMP-1 in the refractory diabetic dermal ulcers treated by autologous Platelet-rich gel].
    He LP; Wang C; Chen DW; Li XJ; Ran XW
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 43(5):757-61. PubMed ID: 23230755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of a cobalt(III) complex of the MMP inhibitor marimastat: a potential hypoxia-activated prodrug.
    Failes TW; Cullinane C; Diakos CI; Yamamoto N; Lyons JG; Hambley TW
    Chemistry; 2007; 13(10):2974-82. PubMed ID: 17171733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects and mechanisms of total glucosides of paeony on joint damage in rat collagen-induced arthritis.
    Zhu L; Wei W; Zheng YQ; Jia XY
    Inflamm Res; 2005 May; 54(5):211-20. PubMed ID: 15953993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis.
    Boyle DL; Kim HR; Topolewski K; Bartok B; Firestein GS
    J Pharmacol Exp Ther; 2014 Feb; 348(2):271-80. PubMed ID: 24244039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Goffin JR; Anderson IC; Supko JG; Eder JP; Shapiro GI; Lynch TJ; Shipp M; Johnson BE; Skarin AT
    Clin Cancer Res; 2005 May; 11(9):3417-24. PubMed ID: 15867243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo endochondral bone formation models allow identification of anti-angiogenic compounds.
    van der Pluijm G; Deckers M; Sijmons B; de Groot H; Bird J; Wills R; Papapoulos S; Baxter A; Löwik C
    Am J Pathol; 2003 Jul; 163(1):157-63. PubMed ID: 12819020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.